Derek Nexus and Sarah Nexus: working together for ICH M7

Size: px
Start display at page:

Download "Derek Nexus and Sarah Nexus: working together for ICH M7"

Transcription

1 Derek Nexus and Sarah Nexus: working together for ICH M7 European ICGM, September 2014 Dr Nicholas Marchetti Product Manager

2 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

3 What does M7 cover? identification categorisation qualification Control of mutagenic impurities to limit potential carcinogenic risk Harmonises guidelines FDA, EMA, Japan Recognises the primacy of the Ames assay

4 Focussing on the identification step Evaluate drug substance, impurities, degradants, (metabolites), intermediates Databases, in-house, literature.. 2 x in silico QSAR Leadscope Multicase Known mutagen Predicted positive Predicted negative Known non-mutagen Expert Review Ames test Expert Review Limit according to TTC or present purge argument for absence Treat as nonmutagenic

5 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

6 Vitic Nexus an authoritative toxicity database Vitic Nexus is a repository of toxicological data Data donated by members Curated and augmented by expert scientists Genotoxicity records In vitro data In vivo data Overall call 146,444 records, 9,014 compounds 10,157 records, 2,658 compounds 15,289 records, 8,510 compounds Contains public datasets and literature including Benchmark, CGX, ISSSTY, IUCLID FDA CDER & CFSAN, JETOC (Japanese Chemical Industry Ecology-Toxicology..) IARC, JETOC, NIHS, NTP, SCCP, SIDS Members also store their own data in Vitic Nexus

7 Data sharing consortia Lhasa facilitate pre-competitive data sharing Members of these consortia also see Aromatic amines 1,664 records 145 compounds Intermediates (includes boronic acid sub-group) 13,834 records 910 compounds Excipients 2,286 records 764 compounds

8 in silico predictions for M7 Use models that predict Ames outcomes 2 complementary methods should be applied One expert rule-based One statistical-based Models should follow OECD Principles for QSAR The absence of alerts from both is sufficient to conclude that the impurity is of no concern Expert review is needed to provide additional evidence for any prediction and to explain conflicting results

9 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

10 Enhancing Derek Nexus for mutagenicity Designed to support expert analysis for M7 Provide additional supporting information Recommend where expert should focus analysis

11 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

12 Sarah Nexus an advanced statistical system Designed to address the ICH M7 guidelines Created with input from the FDA under a Research Collaboration Agreement

13 Making a prediction Query compounds are fragmented Each fragment is assessed Fragments not covered by the training set result in no prediction Relevant hypotheses for each fragment are retrieved Hypothesis, signal, confidence, supporting examples Typically several hypotheses are returned out of domain Overall Prediction = f (prediction, confidence) hypotheses Absence of a strong overall signal equivocal

14 Confidence correlates with accuracy TN 29% TP 31% FP 22% FN 18% TN 40% FP 13% TP 37% FN 10% TN 39% FP 9% TP 50% FN 2% TN 34% FP 4% TP 60% FN 2% FP 6% TN 23% TP 70% FN 1% 1 b. aaa = ssss + ssss PPP = TT TT + FF 0.6 NNN = TT TT + FF % 20-40% 40-60% 60-80% % Sarah confidence score

15 Confidence vs PPV 100% 90% 80% 70% PPV 60% 50% 40% 30% 20% 10% 0% 0% 20% 40% 60% 80% 100% Confidence

16 Sarah Nexus Performance Sarah Nexus has been extensively evaluated by members 100% 80% 83-96% 60-85% 60-89% 38-84% 60% Private 1, n= 744, 28% +ive Private 2, n = 847, 12% +ive Private 3, n= 437, 16% +ive 40% 20% 0% sens + spec 2 TN TN + FP TP TP + FN Coverage Balanced accuracy Specificity Sensitivity Private 4, n = 986, 4% +ive Private 5, n = 1718, 14% +ive Private 6, n = 320, 23% +ive FDA, n=809, 36% +ive Public, n = 11209,49% +ive Sarah Nexus v1 under recommended settings SoT, March 2014

17 Sarah Nexus - Summary Sarah is a statistical approach to mutagenicity Maintains high coverage even with challenging datasets Provides information needed for expert analysis

18 The use of integrated in silico solutions under the proposed ICH M7 guidelines OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions

19 Using in silico predictions M7 explicitly states that in silico predictions should be reviewed with expert knowledge Provide supportive evidence for any prediction Elucidate underlying reasons in case of conflicting results But how will this work in real life? In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey Regulatory Toxicology and Pharmacology, 2012, 62, Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities Regulatory Toxicology and Pharmacology, 2013, 67, 39

20 2 complementary methodologies should be applied Data methodology Expert system uses all Lhasa data including consortia & donated confidential data + data mined on-site expert system human-written rules based upon data & knowledge Statistical system only uses non-confidential data statistical model machine-learning model using a hierarchical network scope of alert hand-written Markush fragments learnt by model interpretability references expert commentary mechanistic explanation scope of alert some supporting examples transparent methodology learning summarised by hypothesis direct link to training set confidence in prediction

21 Using Sarah and Derek together How often do they disagree? When they agree, how accurate are they? 100% 69-85% 62-90% 80% 60% 40% 20% Private Dataset 1 Private Dataset 2 Private Dataset 3 Public Dataset 0% Agreement between Derek Nexus and Sarah Nexus Balanced accuracy for concurring predictions Acknowledgements : All the Lhasa members who worked closely with us during the evaluation and development of Sarah

22 Using Sarah and Derek together A simple conservative approach will increase sensitivity sensitivity 1..but at the cost of accuracy and specificity , = Private dataset accuracy specificity

23 Using Sarah and Derek together When they disagree, which is right? Public Dataset Private Dataset 3 7% 14% 7% 7% 11% 9% 5% 7% 9% 72% 73% 80% 31% 25% 17% 27%

24 Handling conflicting predictions Confidence scores can give an indication Machine-learnt & expert driven rules have been assessed If both models agree Take that consensus prediction If one model has a high confidence prediction Take the most confident prediction If Derek says positive and Sarah has a positive hypothesis (despite being negative overall) Activity is most likely If the positive prediction is of low confidence Activity is unlikely.

25 Handling conflicting predictions Private Dataset 1 Step Step 2 Step 3 Step 4 D and S agree Most confident prediction D says positive, S has positive hypothesis Low confidence positive Accuracy Sensitivity True accuracy Coverage Simple rules give increased coverage without loss of accuracy

26 Ultimately, expert review is needed Decision trees may help guide an expert, but expert review is still essential We have worked with our members to deliver the information needed for expert review

27 Supporting the expert workflow Step 1 Specific Prediction for ICH M7

28 Supporting the expert workflow Derek prediction Predicted negative but there is a ring system to assess

29 Supporting the expert workflow Derek Nexus now shows those compounds from the Lhasa Ames test reference set most closely related to the query

30 Supporting the expert workflow Step 2 Sarah prediction Sarah predicts negative; no positive hypotheses seen Derek and Sarah analysis agree Supporting data from Vitic augments this prediction

31 Supporting the expert workflow Step 3 Vitic search similarity chosen Vitic shows a related active for which there is no obvious cause (no Derek alert fires) and also a related inactive Expert assessment ring system not of concern

32 Possible reasons to over-rule a positive in silico call The presence of a second confounding alert that could have caused the activity a risk with statistical models Minimised with Sarah s recursive learning approach Mechanistic interpretation stereo-electronics preclude reaction through the accepted mechanism such as that described within Derek Similar analogues trigger the same alert and have been tested as inactive were not known to the model

33 What our members say Combined use of two complementary in silico systems such as Derek Nexus and SEP leads to an increase in negative predictivity and sensitivity, up to 99.1% and 94.7% respectively Poster Comparative Evaluation of in Silico Systems for Ames Test Mutagenicity Prediction Ilse Koijen Janssen, GTA Newark Oct 2013, SEP = the pre-release version of Sarah

34 Combined report view

35 Derek Prediction

36 Sarah Prediction

37 Batch View

38 Paper reports

39 Summary M7 will allow predictions of mutagenicity to be submitted Derek has been extended to increase support for expert review Making confident predictions of inactivity Highlighting features worthy of attention Sarah has been designed to provide the statistical 2 nd system Recursive learning and a hierarchical network provide transparency and accuracy The performance of combined predictions has been described Using a number of relevant confidential datasets Examples of expert decision-making illustrate their application Use of Vitic, an authoritative database supports this workflow

40 Questions?

is a knowledge based expert decision support tool for predicting the metabolic fate of chemicals in mammals.

is a knowledge based expert decision support tool for predicting the metabolic fate of chemicals in mammals. is a knowledge based expert decision support tool for predicting the metabolic fate of chemicals in mammals. Reference 08/15 Features and Benefits Summary Efficient Metabolite Structure Elucidation Early

More information

The FDA/CDER Chemical Informatics Program

The FDA/CDER Chemical Informatics Program The FDA/CDER Chemical Informatics Program Naomi Kruhlak, PhD Lead, Chemical Informatics Program Division of Applied Regulatory Science Office of Clinical Pharmacology Office of Translational Sciences FDA

More information

ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK

ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC)

More information

Chemical Risk Assessment in Absence of Adequate Toxicological Data

Chemical Risk Assessment in Absence of Adequate Toxicological Data Chemical Risk Assessment in Absence of Adequate Toxicological Data Mark Cronin School of Pharmacy and Chemistry Liverpool John Moores University England m.t.cronin@ljmu.ac.uk The Problem Risk Analytical

More information

EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE

EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE 6-8 October 2014 Strasbourg, France WORKSHOP IMPURITIES 1 Workshop Session IMPURITIES DNA-reactive impurities: An

More information

Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy

Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy Ella Smoraczewska Lhasa Limited Sales Executive Presentation utline Background & Case Study Regulatory Perspective MI Purge

More information

IMPURITIES IN NEW DRUG PRODUCTS

IMPURITIES IN NEW DRUG PRODUCTS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations

In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations Mark Cronin, Mark Hewitt, Katarzyna Przybylak School of Pharmacy and Chemistry Liverpool John Moores University

More information

Leadscope Genetox Expert Alerts White paper. A new ICH M7 compliant expert alert system to predict the mutagenic potential of impurities.

Leadscope Genetox Expert Alerts White paper. A new ICH M7 compliant expert alert system to predict the mutagenic potential of impurities. Leadscope Genetox Expert Alerts White paper A new ICH M7 compliant expert alert system to predict the mutagenic potential of impurities March 2014 www.leadscope.com 1 A new ICH M7 compliant expert alert

More information

What s New with Impurities in Pharmaceuticals?

What s New with Impurities in Pharmaceuticals? What s New with Impurities in Pharmaceuticals? Southern California Pharmaceutical Discussion Group January 15, 2015 Bernard A. Olsen, Ph.D Olsen Pharmaceutical Consulting, LLC bolsen@comcast.net ICH Q3

More information

QSAR Application Toolbox Workflow. Laboratory of Mathematical Chemistry, Bourgas University Prof. Assen Zlatarov Bulgaria

QSAR Application Toolbox Workflow. Laboratory of Mathematical Chemistry, Bourgas University Prof. Assen Zlatarov Bulgaria QSAR Application Toolbox Workflow Laboratory of Mathematical Chemistry, Bourgas University Prof. Assen Zlatarov Bulgaria Outlook Description General scheme and workflow Basic functionalities Forming categories

More information

Importing pharmaceutical products to China

Importing pharmaceutical products to China Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval

More information

Rapid Pharma Development GmbH. Impurities in the contexts of CMC Development

Rapid Pharma Development GmbH. Impurities in the contexts of CMC Development Rapid Pharma Development GmbH Impurities in the contexts of CMC Development The Challenge What is your Goal? What is your path? Plan for Success Define your goal: Target Product Profile Daily dosage Cost

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:

More information

Regulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc.

Regulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc. Regulatory Expectations for GMP: What s Happening Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc. Topics Background for changes and expectations of regulatory

More information

Read-across and alternative testing strategies for REACH 2018

Read-across and alternative testing strategies for REACH 2018 Read-across and alternative testing strategies for REACH 2018 Jeannette Paulussen, Ph.D. June 24, 2015 Content REACH & Alternative testing strategies In vitro testing and study waivers QSARs and Annex

More information

How to create and interpret the predictive analysis of a compound

How to create and interpret the predictive analysis of a compound How to create and interpret the predictive analysis of a compound Platform with suite of tools Predict & understand biological effects of small molecules & compounds Predict targets and metabolites, potential

More information

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS

More information

Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency

Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency 1 Mission Statement Best possible regulatory decisions to protect public health and environment. Rely on all best

More information

Practical Guide 6. How to report read-across and categories

Practical Guide 6. How to report read-across and categories Practical Guide 6 How to report read-across and categories 2 Practical Guide 6 2.0 Version Changes Date Version 1.0 First version. March 2010 Version 2.0 Revision of the Practical guide addressing structure

More information

General Principles for the Safety Assessment of Excipients

General Principles for the Safety Assessment of Excipients General Principles for the Safety Assessment of Excipients General Characteristics of the Pharmaceutical Excipients Classification of excipients The Safety Assessment of Pharmaceutical Excipients : how

More information

Guidance for Industry Safety Testing of Drug Metabolites

Guidance for Industry Safety Testing of Drug Metabolites Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology

More information

OVERVIEW OF INTEGRATED TEST STRATEGIES METHODS IN APPLICATION TO IN VITRO DATA INDUSTRY EXPERIENCE

OVERVIEW OF INTEGRATED TEST STRATEGIES METHODS IN APPLICATION TO IN VITRO DATA INDUSTRY EXPERIENCE OVERVIEW OF INTEGRATED TEST STRATEGIES METHODS IN APPLICATION TO IN VITRO DATA INDUSTRY EXPERIENCE Joanna Jaworska Central Product Safety - Procter & Gamble Eurocor Strombeek - Bever, Belgium Introduction

More information

Risk assessment and regulation of tattoo inks in the EU

Risk assessment and regulation of tattoo inks in the EU Risk assessment and regulation of tattoo inks in the EU Paul Janssen Current situation: Tattoo application in a regulatory vacuum : Is not a medical treatment Is not a cosmetic treatment No EU-regulation

More information

An exciting opportunity in scientific knowledge base development

An exciting opportunity in scientific knowledge base development An exciting opportunity in scientific knowledge base development Lhasa Limited is a not-for-profit company and educational charity with an enviable reputation for collaboration. Its world leading Derek

More information

A FDA Perspective on Nanomedicine Current Initiatives in the US

A FDA Perspective on Nanomedicine Current Initiatives in the US A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification

More information

Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG

Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation

More information

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution

More information

From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity

From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity Hao Zhu Department of Chemistry The Rutgers Center for Computational and Integrative Biology Rutgers University-Camden

More information

Working with ICH Quality Guidelines - the Canadian Perspective

Working with ICH Quality Guidelines - the Canadian Perspective Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction

More information

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

More information

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY

More information

Overview of Drug Development: the Regulatory Process

Overview of Drug Development: the Regulatory Process Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger

More information

TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS

TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS By Rajkumar Gupta, Managing Director Perfect Pharmaceutical Consultant Pvt. Ltd and Director Global Institute of Regulatory affairs,

More information

A European perspective to networking in drug safety, EU-ADR as example. Prof. Miriam CJM Sturkenboom

A European perspective to networking in drug safety, EU-ADR as example. Prof. Miriam CJM Sturkenboom A European perspective to networking in drug safety, EU-ADR as example has drug safety and effectiveness really improved since thalidomide? Prof. Miriam CJM Sturkenboom The EU-ADR Project (formerly known

More information

Exploring Metabolic Outcomes and Toxic Effects. DiscoveryGate SM Version 1.4 SP2 Workshop Guide

Exploring Metabolic Outcomes and Toxic Effects. DiscoveryGate SM Version 1.4 SP2 Workshop Guide Exploring Metabolic Outcomes and Toxic Effects DiscoveryGate SM Version 1.4 SP2 Workshop Guide Exploring Metabolic Outcomes and Toxic Effects DiscoveryGate Version 1.4 SP2 Workshop Guide Elsevier MDL

More information

Guidance for Industry

Guidance for Industry Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Division of Bioinformatics and Biostatistics

Division of Bioinformatics and Biostatistics Division of Bioinformatics and Biostatistics Weida Tong, Ph.D. The views presented do not necessarily reflect the views of the FDA. 1 Established on May 20 th, 2012. Three Branches: Division Overview Bioinformatics

More information

REACH. Scope REGISTRATION. The Current EU Chemicals Policy REACH

REACH. Scope REGISTRATION. The Current EU Chemicals Policy REACH Introduction to the New Chemicals Policy REACH REACH and Developing Countries Brussels 28-29 October 2004 Eva Sandberg DG Environment, European Commission The Current EU Chemicals Policy Problems Existing

More information

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance

More information

CTD Dossier Preparation. Sr.Manager-Regulatory Affairs

CTD Dossier Preparation. Sr.Manager-Regulatory Affairs CTD Dossier Preparation K. Srikantha Reddy Sr.Manager-Regulatory Affairs Medreich Limited Srikanth.k@medreich.com CTD Dossier Preparation CTD (Common Technical Document) contains 5 modules Module 1 Module

More information

Examples from Industrial Practice in Lead Development. Wolfgang Muster F. Hoffmann-La Roche Ltd.

Examples from Industrial Practice in Lead Development. Wolfgang Muster F. Hoffmann-La Roche Ltd. Examples from Industrial Practice in Lead Development Wolfgang Muster F. Hoffmann-La Roche Ltd. Areas Computer-Aided Molecular Modeling (CAMM) * Absorption, Distribution, Metabolism and Excretion (ADME)

More information

MedDRA in pharmacovigilance industry perspective

MedDRA in pharmacovigilance industry perspective MedDRA in pharmacovigilance industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International

More information

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants

Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current

More information

Submission of scientific peer-reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 1, 2

Submission of scientific peer-reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 1, 2 GUIDANCE OF EFSA - DRAFT Submission of scientific peer-reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 1, 2 ABSTRACT European Food Safety Authority

More information

Biological importance of metabolites. Safety and efficacy aspects

Biological importance of metabolites. Safety and efficacy aspects Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural

More information

Medicine Safety Glossary

Medicine Safety Glossary The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

Impurity Profiles in Active Pharmaceutical Ingredients

Impurity Profiles in Active Pharmaceutical Ingredients Impurity Profiles in Active Pharmaceutical Ingredients EU/Swissmedic GMP Workshop Beijing University, Sept. 20 22, 2006 Dr. Susanne Keitel Federal Institute for Drugs and Medical Devices (BfArM), Germany

More information

Validating Methods using Waters Empower TM 2 Method. Validation. Manager

Validating Methods using Waters Empower TM 2 Method. Validation. Manager Validating Methods using Waters Empower TM 2 Method Validation Manager (MVM) Anders Janesten Nordic Informatics Sales Specialist 2008 Waters Corporation Decision-centric centric method development information

More information

Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99

Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99 Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99 Printed in the USA. All rights reserved. Copyright 1999 Drug Information Association Inc. THE ACTIVE PHARMACEUTICAL INGREDIENTS STARTING

More information

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace

More information

FEMA, TOEAST - Japan's stockpile of Electronic Tools

FEMA, TOEAST - Japan's stockpile of Electronic Tools Electronic Tools used for Existing and New Chemicals Government/Industry Activities Japanese perspective OECD Workshop on Electronic tools Ottawa, Canada October 2-4,2002 1 Introduction Kotaro YOSHIDA

More information

REACH - Registration and enforcement. Latest trends in REACH and CLP Tokyo 30 March 2010. Laura Walin ECHA Guidance and helpdesk

REACH - Registration and enforcement. Latest trends in REACH and CLP Tokyo 30 March 2010. Laura Walin ECHA Guidance and helpdesk REACH - Registration and enforcement Latest trends in REACH and CLP Tokyo 30 March 2010 Laura Walin ECHA Guidance and helpdesk REACH and ECHA REACH Regulation entered into force 1 June 2007 ECHA was created

More information

BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS

BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS 1. The Technology Strategy sets out six areas where technological developments are required to push the frontiers of knowledge

More information

Implementation strategy for ISO IDMP in EU

Implementation strategy for ISO IDMP in EU Implementation strategy for ISO IDMP in EU Paolo Alcini Head of Data Standardisation and Analytics Business Data & Analytics Information Management EMA An agency of the European Union The EU ISO IDMP Task

More information

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) November 2012 EMA/CHMP/ICH/425213/2011 ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) Step 5 Transmission to CHMP May

More information

ICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance

ICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance ICH Public Meeting October 2, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance The Current State of Pharmaceutical Manufacturing Inability to predict

More information

Strategic Benefits of an Online Clinical Data Repository

Strategic Benefits of an Online Clinical Data Repository Strategic Benefits of an Online Clinical Data Repository 5625 Dillard Drive Suite 205 Cary, NC 27518 www.pharsight.com Strategic Benefits of an Online Clinical Data Repository Contents Introduction 2 The

More information

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5 European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND

More information

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.

GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS. GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au

More information

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations

More information

Getting Ready for REACH Advanced Solutions for Compliance. John Phyper, CSO & EVP Atrion International Inc.

Getting Ready for REACH Advanced Solutions for Compliance. John Phyper, CSO & EVP Atrion International Inc. Getting Ready for REACH Advanced Solutions for Compliance John Phyper, CSO & EVP Atrion International Inc. Getting Ready for REACH Advanced Solutions for Compliance Introduction What is REACH? What Does

More information

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory

More information

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and

More information

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES Division of Extramural Research and Training

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES Division of Extramural Research and Training NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES Division of Extramural Research and Training NATIONAL ADVISORY ENVIRONMENTAL HEALTH SCIENCES COUNCIL May 12-13, 2010 Concept Clearance Small Business

More information

Q8(R2): Pharmaceutical Development

Q8(R2): Pharmaceutical Development ICH-GCG ASEAN Q8(R2): Pharmaceutical Development Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference

More information

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories

More information

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD 1 Summary Hypothesis Generation Candidate Development Commercialization Target Identification

More information

Chapter 12: SPECIFIC TARGET ORGAN SYSTEMIC TOXICITY (TOST) FOLLOWING A SINGLE EXPOSURE

Chapter 12: SPECIFIC TARGET ORGAN SYSTEMIC TOXICITY (TOST) FOLLOWING A SINGLE EXPOSURE Chapter 12: SPECIFIC TARGET ORGAN SYSTEMIC TOXICITY (TOST) FOLLOWING A SINGLE EXPOSURE DEFINITIONS 1. Classification identifies the chemical substance as being a specific target organ/systemic toxicant

More information

Risk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS) http://www.who.int/foodsafety/en/

Risk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS) http://www.who.int/foodsafety/en/ Risk Assessment in Chemical Food Safety Dept. of Food Safety and Zoonoses (FOS) http://www.who.int/foodsafety/en/ Risk Analysis Paradigm Internationally Scientific data analysis Risk Assessment WHO & FAO

More information

Lead optimization services

Lead optimization services Lead optimization services The WIL Research Company (WRC) has extensive experience in fast track tailor-made screening strategies to help you with the challenging task of selecting your best candidate

More information

ANTARES A new project for Alternative Methods and REACH

ANTARES A new project for Alternative Methods and REACH newsletter October 2010 ANTARES A new project for Alternative Methods and REACH Alternative Non-Testing methods Assessed for REACH Substances www.antares-life.eu LIFE08 ENV/IT/00435 2 ANTARES Newsletter

More information

Use of Predictive ADME in Library Profiling and Lead Optimization

Use of Predictive ADME in Library Profiling and Lead Optimization Use of Predictive ADME in Library Profiling and Lead Optimization Osman F. Güner and Robert D. Brown 223 rd ACS National Meeting April 2002, Orlando Florida Why Predictive ADME in Early Discovery? The

More information

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge

More information

Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.

Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd. Causality Assessment in Practice Pharmaceutical Industry Perspective Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd., Basel Disclaimer: The opinions expressed in this presentation are

More information

Ah-Reum Seo of Chemservice Asia introduces the forthcoming chemicals regulation for South Korea

Ah-Reum Seo of Chemservice Asia introduces the forthcoming chemicals regulation for South Korea Environment & Regulations The best strategy to implement K-REACH Ah-Reum Seo of Chemservice Asia introduces the forthcoming chemicals regulation for South Korea Most existing chemicals on the market have

More information

Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP)

Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP) Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP) Summary This document examines the key aspects of the CLP

More information

ROADMAP. A. Context and problem definition

ROADMAP. A. Context and problem definition ROADMAP TITLE OF THE INITIATIVE Defining criteria for identifying Endocrine Disruptors in the context of the implementation of the Plant Protection Product Regulation and Biocidal Products Regulation LEAD

More information

Current version dated 5 March 2012

Current version dated 5 March 2012 M3(R2) Implementation Working Group M3(R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Questions & Answers

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,

More information

ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals International Conference on Harmonisation of Technical Requirements

More information

Chemical Screening Visualization Tool: Resource for Rapid Chemical Assessment

Chemical Screening Visualization Tool: Resource for Rapid Chemical Assessment Chemical Screening Visualization Tool: Resource for Rapid Chemical Assessment Mario Chen Environmental & Toxicological Modeling DuPont Haskell Global Centers for Health & Environmental Sciences 2 Abstract

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

Topic 3 RISK MANAGEMENT APPROACH for CMC SUBMISSIONS AND REVIEW. Topic Leaders Kim Huynh-Ba, Pharmalytik Lynn Gold, Camargo

Topic 3 RISK MANAGEMENT APPROACH for CMC SUBMISSIONS AND REVIEW. Topic Leaders Kim Huynh-Ba, Pharmalytik Lynn Gold, Camargo Topic 3 RISK MANAGEMENT APPROACH for CMC SUBMISSIONS AND REVIEW Topic Leaders Kim Huynh-Ba, Pharmalytik Lynn Gold, Camargo Introduction to Speakers John Duan, Clinical Pharmacology & Biopharmaceutics Reviewer,

More information

Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS

Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS U.S. Department of Health and Human Services Food and Drug Administration Center for Biologic Evaluation and Research (CBER) Center for

More information

Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe

Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts

More information

Workshop B Control Strategy

Workshop B Control Strategy ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation

More information

Collaborations between Official Statistics and Academia in the Era of Big Data

Collaborations between Official Statistics and Academia in the Era of Big Data Collaborations between Official Statistics and Academia in the Era of Big Data World Statistics Day October 20-21, 2015 Budapest Vijay Nair University of Michigan Past-President of ISI vnn@umich.edu What

More information

Roles & Responsibilities of the Sponsor

Roles & Responsibilities of the Sponsor Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from

More information

Cheminformatics and its Role in the Modern Drug Discovery Process

Cheminformatics and its Role in the Modern Drug Discovery Process Cheminformatics and its Role in the Modern Drug Discovery Process Novartis Institutes for BioMedical Research Basel, Switzerland With thanks to my colleagues: J. Mühlbacher, B. Rohde, A. Schuffenhauer

More information

Dr Alexander Henzing

Dr Alexander Henzing Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander

More information

Auditing as a Component of a Pharmaceutical Quality System

Auditing as a Component of a Pharmaceutical Quality System Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a

More information

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs. 15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2

More information

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

An FDA Perspective on Post- Approval Change Management for PAT and RTRT An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes

More information

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements

Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,

More information

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS

More information